Compare SAP SE (SAP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Zoetis Inc — how do they compare? SAP SE trades at $202.88 (market cap $240.81B), while Zoetis Inc trades at $73.59 (market cap $31.14B). The key difference: SAP SE is far larger — about 7.7× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| SAP | ZTS | |
|---|---|---|
Market Cap | $240.81B | $31.14B |
Sector | Technology | Health |
52-Week High | $280.46 | $156.76 |
52-Week Low | $146.38 | $71.91 |
Enterprise Value | $239.52B | $38.70B |
Dividend Yield | 1.4% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP stock trades at $203.07, down 2.63% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong Q2 2026 revenue growth driven by cloud demand, though it missed EPS estimates. Fundamentals show robust profitability with a 20.41% net income margin and rising cash flow from operations to $9.16B in 2025. Recent news highlights AI and cloud strategy advancements, with shares reacting positively to analyst upgrades and earnings resilience.
The outlook is cautiously optimistic, with a consensus price target of $209.67 offering modest upside. Investment opportunities lie in SAP's cloud transition and AI integration, but risks include execution challenges, margin pressure from investments, and competitive threats. The stock's valuation at a P/E of 27.16 may limit near-term gains if growth slows.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
